5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
CYP2C19 O
inhibitors O
: O
Avoid O
concomitant O
use O
of O
omeprazole O
or O
esomeprazole O
. O

( O
5.1 O
) O
* O
Bleeding O
: O
Plavix O
increases O
risk O
of O
bleeding O
. O

( O
5.2 O
) O
* O
Discontinuation O
: O
Premature O
discontinuation O
increases O
risk O
of O
cardiovascular O
events O
. O

Discontinue O
5 O
days O
prior O
to O
elective O
surgery O
that O
has O
a O
major O
risk O
of O
bleeding O
. O

( O
5.3 O
) O
* O
Thrombotic O
thrombocytopenic O
purpura O
( O
TTP O
) O
has O
been O
reported O
. O

( O
5.4 O
) O
* O
Cross-reactivity O
among O
thienopyridines O
has O
been O
reported O
. O

( O
5.5 O
) O
5.1 O
Diminished O
Antiplatelet O
Activity O
in O
Patients O
with O
Impaired O
CYP2C19 O
Function O
Clopidogrel O
is O
a O
prodrug O
. O

Inhibition B-NonOSE_AE
of I-NonOSE_AE
platelet I-NonOSE_AE
aggregation I-NonOSE_AE
by O
clopidogrel O
is O
achieved O
through O
an O
active O
metabolite O
. O

The O
metabolism O
of O
clopidogrel O
to O
its O
active O
metabolite O
can O
be O
impaired O
by O
genetic B-Not_AE_Candidate
variations I-Not_AE_Candidate
in I-Not_AE_Candidate
CYP I-Not_AE_Candidate
2 I-Not_AE_Candidate
C I-Not_AE_Candidate
1 I-Not_AE_Candidate
9 I-Not_AE_Candidate
[ O
see O
Boxed O
Warning O
] O
. O

The O
metabolism O
of O
clopidogrel O
can O
also O
be O
impaired O
by O
drugs O
that O
inhibit O
CYP2C19 O
, O
such O
as O
omeprazole O
or O
esomeprazole O
. O

Avoid O
concomitant O
use O
of O
Plavix O
with O
omeprazole O
or O
esomeprazole O
because O
both O
significantly O
reduce B-NonOSE_AE
the I-NonOSE_AE
antiplatelet I-NonOSE_AE
activity I-NonOSE_AE
of O
Plavix O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

5.2 O
General O
Risk O
of O
Bleeding O
Thienopyridines O
, O
including O
Plavix O
, O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
. O

Thienopyridines O
inhibit B-NonOSE_AE
platelet I-NonOSE_AE
aggregation I-NonOSE_AE
for O
the O
lifetime O
of O
the O
platelet O
( O
7-10 O
days O
) O
. O

Because O
the O
half-life O
of O
clopidogrel O
's O
active O
metabolite O
is O
short O
, O
it O
may O
be O
possible O
to O
restore O
hemostasis O
by O
administering O
exogenous O
platelets O
; O
however O
, O
platelet O
transfusions O
within O
4 O
hours O
of O
the O
loading O
dose O
or O
2 O
hours O
of O
the O
maintenance O
dose O
may O
be O
less O
effective O
. O

5.3 O
Discontinuation O
of O
Plavix O
Discontinuation O
of O
Plavix O
increases O
the O
risk O
of O
cardiovascular B-NonOSE_AE
events I-NonOSE_AE
. O

If O
Plavix O
must O
be O
temporarily O
discontinued O
( O
e.g. O
, O
to O
treat O
bleeding B-Not_AE_Candidate
or O
for O
surgery O
with O
a O
major O
risk O
of O
bleeding B-Not_AE_Candidate
) O
, O
restart O
it O
as O
soon O
as O
possible O
. O

When O
possible O
, O
interrupt O
therapy O
with O
Plavix O
for O
five O
days O
prior O
to O
such O
surgery O
. O

Resume O
Plavix O
as O
soon O
as O
hemostasis O
is O
achieved O
. O

5.4 O
Thrombotic B-OSE_Labeled_AE
Thrombocytopenic I-OSE_Labeled_AE
Purpura I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TTP I-OSE_Labeled_AE
) O
TTP B-OSE_Labeled_AE
, O
sometimes O
fatal O
, O
has O
been O
reported O
following O
use O
of O
Plavix O
, O
sometimes O
after O
a O
short O
exposure O
( O
< O
2 O
weeks O
) O
. O

TTP B-NonOSE_AE
is O
a O
serious O
condition O
that O
requires O
urgent O
treatment O
including O
plasmapheresis O
( O
plasma O
exchange O
) O
. O

It O
is O
characterized O
by O
thrombocytopenia B-NonOSE_AE
, O
microangiopathic B-NonOSE_AE
hemolytic I-NonOSE_AE
anemia I-NonOSE_AE
( O
schistocytes B-NonOSE_AE
[ O
fragmented O
RBCs O
] O
seen O
on O
peripheral O
smear O
) O
, O
neurological B-NonOSE_AE
findings I-NonOSE_AE
, O
renal B-NonOSE_AE
dysfunction I-NonOSE_AE
, O
and O
fever B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.5 O
Cross-Reactivity O
among O
Thienopyridines O
Hypersensitivity B-OSE_Labeled_AE
including O
rash B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
or O
hematologic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
receiving O
Plavix O
, O
including O
patients O
with O
a O
history B-Not_AE_Candidate
of I-Not_AE_Candidate
hypersensitivity O
or O
hematologic I-Not_AE_
Candidate B-Not_AE_Candidate
reac I-Not_AE_Candidate
tion I-Not_AE_Candidate
to O
other O
thienopyridines O
[ O
see O
Contraindications O
( O
4.2 O
) O
and O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

